Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
71,6 CHF | -0,69% | +0,28% | +40,67% |
Métier
Nombre d'employés: 319
Ventes par activité
CHF en Millions | 2021 | Poids | 2022 | Poids | Delta |
---|---|---|---|---|---|
Own Products
52,0
%
| 43 | 60,6 % | 53 | 52,0 % | +25,05% |
Licence Fees, Up-front Fees and Milestones
23,8
%
| 6 | 8,5 % | 24 | 23,8 % | +310,51% |
Generic Products, Specialty Drugs and Related Services
12,9
%
| 14 | 19,4 % | 13 | 12,9 % | -3,41% |
Royalties
9,7
%
| 6 | 8,6 % | 10 | 9,7 % | +63,17% |
Other
1,6
%
| 2 | 2,9 % | 2 | 1,6 % | -17,40% |
Ventes par région
CHF en Millions | 2021 | Poids | 2022 | Poids | Delta |
---|---|---|---|---|---|
Italy
100,0
%
| 70 | 100,0 % | 102 | 100,0 % | +45,72% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Chief Executive Officer | 61 | 01/01/06 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01/06/16 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/06/05 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 01/09/11 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 01/01/01 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 10/01/22 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 01/01/22 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 28/05/21 |
Founder | 69 | 01/01/97 | |
Director/Board Member | 64 | 01/01/06 | |
Director/Board Member | 69 | 01/04/12 | |
Director/Board Member | 65 | 01/03/16 | |
Chief Executive Officer | 61 | 01/01/06 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 17 543 522 | 7 805 026 ( 44,49 %) | 1 490 681 ( 8,497 %) | 44,49 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
1 283 390 | 7,32% | 101 593 999 $ |
Coordonnées société
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.comSociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Pharmaceuticals: Major
| |
Cosmo Technologies Ltd.
Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Secteur
Ventes par activité
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+40,67% | 1,26 Md | |
+25,83% | 661 Md | |
+27,00% | 566 Md | |
-6,76% | 352 Md | |
+20,34% | 332 Md | |
+3,00% | 283 Md | |
+13,09% | 231 Md | |
+5,46% | 200 Md | |
-9,61% | 195 Md | |
-6,26% | 145 Md |
- Bourse
- Actions
- Action COPN
- Société Cosmo Pharmaceuticals N.V.